Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen Richter ...

We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts. In this article, we are going to ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised, ...

Goldman Sachs analyst Salveen Richter notes that Biogen’s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in ...

The company ended the year with $11.2 billion in cash and investments. Salveen Richter, Goldman Sachs: Questioned retail pharmacy and P&T committee pre-launch efforts for JOURNAVX. COO Stuart ...

Salveen Richter, Goldman Sachs: Inquired about BLU-808’s safety profile and potential dosing strategies. CMO Becker Hewes noted the drug’s wide therapeutic index and plans to test various ...

On the HIV business, Goldman Sachs analyst Salveen Richter says commentary was largely consistent with the recent investor event. The analyst sees challenges in oncology due to competition ...

Goldman Sachs US Biotechnology Analyst Salveen Richter explains on "Bloomberg Markets." (Bloomberg) -- Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected ...